Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
Public ClinicalTrials.gov record NCT01829113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)
Study identification
- NCT ID
- NCT01829113
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Interventions
- OGX-427 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2013
- Primary completion
- Apr 18, 2017
- Completion
- Apr 18, 2017
- Last update posted
- Jun 7, 2018
2013 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists-South | Fort Myers | Florida | 33916 | — |
| Florida Hospital Cancer Insitute | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists-North | St. Petersburg | Florida | 33705 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Research Medical Center | Kansas City | Missouri | 64132 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Hematology-Oncology Associates of Northern NJ | Morristown | New Jersey | 07932 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
| Tennessee Oncology - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Peninsula Cancer Institute | Newport News | Virginia | 23601 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01829113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2018 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01829113 live on ClinicalTrials.gov.